Related Questions
How will the size and timing of the buy‑back affect IPSEN's earnings per share and price momentum in the short term?
What are the details of the funding source and any potential impact on IPSEN's balance sheet or credit metrics?
How does this buy‑back programme compare to recent buy‑backs by peer pharmaceutical companies in terms of scale, pricing and shareholder return expectations?